Inhibikase holds $193.3m cash as PAH drug trial clears 28 countries

Inhibikase Therapeutics ended the third quarter with $193.3m in cash against a quarterly net loss of $20.5m, according to results published on 10 November. The figures show the funding position of a company whose value rests on a single late-stage asset, IKT-001, an oral anti-proliferative for pulmonary arterial hypertension (PAH). The summary we reviewed did not include runway guidance, so we cannot say how long management expects the cash to last.

The company's pivotal study, IMPROVE-PAH, has now been cleared to proceed in 28 countries. Of 180 planned trial sites, 79 are open. That leaves more than half of the planned network still to be activated, so site start-up remains a variable for how quickly the study can enrol. Enrolment figures and trial design details were not available to us.

The next scheduled data point is an interim safety analysis from Part A, which Inhibikase expects in the first half of 2027. Separately, the company has begun regulatory filings that would let patients in Part B receive IKT-001 alongside sotatercept. Those filings may need further review in the participating countries.

In July 2026 the US Food and Drug Administration's Office of Orphan Products Development granted IKT-001 orphan status. This is not a marketing authorisation. As general context, orphan designation can bring development incentives and, if a product is later approved, a period of market exclusivity, but it says nothing about whether the drug works.

Context on the combination plan: sotatercept is an already-marketed PAH treatment sold by Merck as Winrevair. Testing IKT-001 on top of it suggests Inhibikase wants the drug evaluated within current treatment practice rather than only as a standalone option. The summary does not say how the company sees the commercial implications.